EULAR 2025 Highlights Podcast

In this episode, Medicom’s correspondent covers 6 presentations from annual meeting of the European Alliance of Associations for Rheumatology (EULAR 2025), held in Barcelona, Spain, from 11-14 June 2025.

The topics discussed are:

1. First-in-class oral TYK2 inhibitor shows rapid efficacy in PsA

Deucravacitinib, a first-in-class oral TYK2 inhibitor, demonstrated clinical benefits in psoriatic arthritis over placebo at 16 weeks, with rapid clinical response, favourable safety profile, and signs of radiographic progression inhibition.

2. Beneficial treatment with leflunomide and hydroxychloroquine combination in Sjögren’s Disease

A significant reduction in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at week 24 was the successful primary outcome of the combination of leflunomide and hydroxychloroquine compared with placebo. Significant improvements were also seen in IgG, rheumatoid factor, and complement C4 levels.

3. Use of Axia significantly improves axSpA outcomes

The novel digital therapeutic Axia significantly and clinically improved disease activity, functional ability, and quality-of-life in patients with axial spondyloarthritis compared with standard care. These findings underscore the value of integrating digital therapeutics into routine rheumatological care.

4. Inhibition of TLR7 and 8: A new way to treat lupus?

Enpatoran, a toll-like receptor 7 and

8 inhibitor, showed potential in patients with active systemic lupus erythematosus and cutaneous lupus erythematosus. Although the primary endpoint of the British Isles Lupus Assessment Group-based Composite Lupus Assessment dose response was not met, response rates and secondary outcomes support further investigations.

5. Gout: novel compound as a future option for refractory patients?

Treatment with SAP-001, a first-in-class urate-lowering agent targeting a novel renal urate transport mechanism, resulted in successful reduction of serum urate levels to ≤6 mg/dL in 43.8%–70% of patients, across different dosing regimens. A dose-response effect could not be established.

6. Rapid radiographic improvement with IL-23 blockade in biologic-naïve PsA patients

A 24-week analysis of the phase 3b APEX study showed that guselkumab, a monoclonal antibody targeting the IL-23p19 subunit, significantly inhibits structural joint damage and improves clinical outcomes in biologic-naïve patients with active psoriatic arthritis.

Enjoy listening!

Copyright ©2025 Medicom Medical Publishers



Posted on 30 June 202530 June 2025